Heartburn & BP Med Class Action Settlement, Claim with No Receipts!
If you purchased Sun Pharmaceutical Industries and Ranbaxy Inc. products including generic Nexium and generic or branded Diovan and Valcyte, then don’t miss this class action lawsuit!. The companies have agreed to a $145 million class action settlement to resolve claims the companies worked together to fix the price of these medications. This lawsuit is known as In Re Ranbaxy Generic Drug Application Antitrust Litigation, Master File No. 19-md-02878 pending in the United States District Court for the District of Massachusetts.
How do I file a claim?
Head on over to the website, where you can learn more and file a claim. You can file online, and you can also file by mail.
What’s this settlement about?
The Lawsuit alleges that Defendants violated federal racketeering, state antitrust, and state consumer protection laws. Plaintiffs allege that, in 2007-2008, generic-drug-maker Ranbaxy wrongfully obtained from the FDA “tentative approval” for a series of first-to-file abbreviated new drug applications (“ANDAs”), including for generic versions of Nexium, Diovan, and Valcyte. Plaintiffs allege that Ranbaxy did so by misrepresenting both the manufacturing conditions of its plants (including one in Paonta Sahib, India) and the results of analyses conducted about the integrity of data generated at those plants. Plaintiffs also allege that those tentative approvals secured for Ranbaxy “180-day exclusivity” status, which enabled Ranbaxy to block other generics from gaining FDA approval until after Ranbaxy’s drugs entered the markets. Plaintiffs allege that had Ranbaxy not made misrepresentations to the FDA, the FDA would not have granted the tentative approvals and generic entry by one or more other companies would have occurred sooner than it did.
What Products are Included?
Nexium (esomeprazole magnesium) is a heartburn medication, Valcyte (valganciclovir hydrochloride) is a prescription antiviral medication, and Diovan (valsartan) is a prescription blood pressure medication.
Who is eligible for a refund?
There are both nationwide classes and state-based classes. The “Indirect Purchaser States” are: Arizona, California, the District of Columbia, Florida, Hawaii, Iowa, Massachusetts, Maine, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Oregon, South Dakota, Vermont, West Virginia, and Wisconsin. If you’re not in one of these states, you still may qualify for the nationwide class.
You are a member of the Class(es) if you are a third-party payor and you purchased or provided reimbursement for prescription drugs as described below:
(1) Generic Nexium Nationwide Class. Between May 27, 2014 and February 1, 2019, you purchased or paid for some or all of the purchase price of AB-rated generic versions of Nexium in the United States and its territories;
(2) Brand or Generic Diovan Nationwide Class. Between September 28, 2012 and April 1, 2020, you purchased or paid for some or all of the purchase price of Diovan and/or AB-rated generic versions of Diovan in the United States and its territories; or
(3) Brand or Generic Valcyte Nationwide Class. Between August 1, 2014 and April 1, 2020, you purchased or paid for some or all of the purchase price of Valcyte and/or AB-rated generic versions of Valcyte in the United States and its territories.
Is a receipt required?
Proof of purchase is not required to file a claim. However, they may request documentation at a later date.
How much will I get back?
Payments will be based on a number of factors, including the number of valid claims filed by all members of the Class and the dollar value of each member of the Classes’ purchase(s) in proportion to the total claims filed. Complete details of how your recovery will be calculated are in the detailed Plan of Allocation, which can be viewed at www.RanbaxyTPPLitigation.com.
Plan of Allocation will govern distributions from the net proceeds of the $145 million settlement fund. “Diovan Fund” shall mean 72.6% of the Net Settlement Fund, which shall be distributed to Class Members who submit Qualifying Diovan Claims. “Nexium Fund” shall mean 26.2% of the Net Settlement Fund, which shall be distributed to Class Members who submit Qualifying Nexium Claims. To be clear, and as defined below, purchases of brand Nexium are not Qualifying Nexium Claims. “Valcyte Fund” shall mean 1.2% of the Net Settlement Fund, which shall be distributed to Class Members who submit Qualifying Valcyte Claims.
What’s the deadline to file a claim?
October 11, 2022.
What is a class action lawsuit settlement?
For example, a class action lawsuit is one with multiple plaintiffs. In other words, there are more than one person being represented by the lawsuit. In other words, a plaintiff or plaintiffs file the case on behalf of many people who were affected by aren’t involved in the actual suit. For example, if you purchased an item that was later determined to be involved in a class action lawsuit, you may be entitled to compensation. If you’re included in the class or group of people affected, then you can file a claim to receive money, coupons or replacement products. But, each case is different, and each will specify who is included. In addition, class action lawsuits may require proof that you are part of the group of affected people. In this case, proof of purchase or other specified proof is needed. However, in some cases, no proof is required. In that case, you can file a claim without proving that you are part of the class of people affected. Of course, when you file a claim you are doing so under penalty of perjury. So, do not file if you do not qualify.
Want more like this?
Get ALL the money owed to you in all our Top Class Action Lawsuits with No Receipts *HERE*!